Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ARVN · NASDAQ · Pharmaceutical Preparations
$6.46−0.28 (−4.15%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Arvinas (ARVN) · oqro.io/stocks/ARVN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 16, 2026
D. E. Shaw & Co., L.P. cut its ARVN stake below 5% (4.9%)SourceInsider trade · Traded Nov 9, 2026 · Filed Nov 9, 2026
Officer sold ~$1.5K of ARVN shares in the open marketSourceInsider trade · Traded Sep 22, 2025 · Filed Sep 24, 2025
Director purchased ~$227K of ARVN shares in the open marketSourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
RTW Investments, LP no longer reported ARVN for Q2 2025SourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed Aug 6, 2025
Perceptive Advisors LLC no longer reported ARVN for Q1 2025SourceInsider trade · Traded Jun 24, 2025 · Filed Jun 24, 2025
CFO sold ~$43K of ARVN shares in the open marketSourceInsider trade · Traded Jun 17, 2025 · Filed Jun 18, 2025
Officer sold ~$19K of ARVN shares in the open marketSourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 14, 2025
Bellevue Group AG no longer reported ARVN for Q1 2025SourceInsider trade · Traded Mar 18, 2025 · Filed Mar 19, 2025
Officer sold ~$74K of ARVN shares in the open marketSourceInsider trade · Traded Feb 24, 2025 · Filed Feb 25, 2025
CEO sold ~$439K of ARVN shares in the open marketSourceInsider trade · Traded Feb 24, 2025 · Filed Feb 25, 2025
CEO sold ~$85K of ARVN shares in the open marketSourceInsider trade · Traded Feb 24, 2025 · Filed Feb 25, 2025
Officer sold ~$123K of ARVN shares in the open marketSourceInsider trade · Traded Feb 24, 2025 · Filed Feb 25, 2025
Officer sold ~$51K of ARVN shares in the open marketSourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
Paradigm Biocapital Advisors LP disclosed a reduced position in ARVN for Q3 2024SourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
RTW Investments, LP disclosed a reduced position in ARVN for Q3 2024SourceInsider trade · Traded Nov 8, 2023 · Filed Nov 12, 2024
Officer sold ~$3.9K of ARVN shares in the open marketSourceInsider trade · Traded Nov 7, 2024 · Filed Nov 12, 2024
Officer sold ~$6.4K of ARVN shares in the open marketSourceInsider trade · Traded Feb 24, 2025 · Filed Feb 25, 2025
Officer sold ~$28K of ARVN shares in the open marketSourceInsider trade · Traded Feb 24, 2025 · Filed Feb 25, 2025
Officer sold ~$20K of ARVN shares in the open marketSourceInsider trade · Traded Feb 24, 2025 · Filed Feb 25, 2025
Officer sold ~$19K of ARVN shares in the open marketSourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Perceptive Advisors LLC disclosed a reduced position in ARVN for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Paradigm Biocapital Advisors LP no longer reported ARVN for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
RTW Investments, LP disclosed an increased position in ARVN for Q4 2024Source